News Column

DGAP-Adhoc: WILEX AG: WILEX returns rights from collaboration in oncology to UCB and UCB waives repayment of the shareholder loan

May 21, 2014

WILEX AG / Key word(s): Agreement 21.05.2014 12:48 Dissemination of an Ad hoc announcement according to 15 WpHG, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- WILEX returns rights from collaboration in oncology to UCB and UCB waives repayment of the shareholder loan Munich, Germany, 21 May 2014. WILEX AG (ISIN DE0006614720 / WL6 / FSE) today announced that due to the strategic re-alignment implemented at WILEX AG, the collaboration agreement for the clinical product candidates WX-554 and WX-037 and for three preclinical antibody programmes has been terminated by mutual agreement. WILEX will return all rights granted and will transfer all intellectual property, data and documents generated in connection with the programmes to UCB. Furthermore an agreement regarding an antibody programme for non-oncology indications signed last year has been terminated. WILEX will receive a final payment for reimbursement of R&D expenses. UCB has agreed to waive repayment of the EUR 2.5 million shareholder loan granted in December 2010 on completion of the transfer. This does not affect UCB's role as a shareholder of WILEX AG. --------------------------------------------------------------------------- Information and Explaination of the Issuer to this News: About WILEXWILEX AG is a biopharmaceutical company based in Munich, Germany. Focused on oncology, the Company develops diagnostic and therapeutic product candidates based on antibodies and small molecules, which are available for out-licensing. The subsidiary Heidelberg Pharma GmbH offers preclinical contract research services and an antibody drug conjugate (ADC) technology platform. Our customers and partners include leading international pharmaceutical companies. WILEX is listed at the Frankfurt Stock Exchange: ISIN DE0006614720 / WKN 661472 / Symbol WL6. More information is available at Contact IR/PR support WILEX AGMC Services AG Corporate Communications Katja Arnold (CIRO) Sylvia Wimmer Tel.: +49 (0)89-210 228-40 Tel.: +49 (0)89-41 31 38-29 Mobile: +49 (0)160 9360 3022 Email: investors[at] Email: katja.arnold[at] Grillparzerstr. 10, 81675 Munich This communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as 'estimates', 'believes', 'expects', 'may', 'will', 'should', 'future', 'potential' or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial position, earnings, achievements, or industry results, to be materially different from any future results, earnings or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments. 21.05.2014 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at and --------------------------------------------------------------------------- Language: English Company: WILEX AG Grillparzerstr. 10 81675 MÜnchen Germany Phone: +49 (0)89 41 31 38 - 0 Fax: +49 (0)89 41 31 38 - 99 E-mail: Internet: ISIN: DE0006614720 WKN: 661472 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, DÜsseldorf, MÜnchen, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------

For more stories on investments and markets, please see HispanicBusiness' Finance Channel

Source: DGAP Ad Hoc Disclosures

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters